Malaria prevention in infants may strengthen immunity for years
NCT ID NCT04978272
First seen Apr 26, 2026 · Last updated Jun 22, 2026 · Updated 6 times
Summary
This Phase 3 trial in Uganda tests whether giving young children monthly malaria prevention medicine (dihydroartemisinin-piperaquine) from 8 weeks to 1 or 2 years of age helps them develop stronger immunity against malaria later. 924 children are enrolled and followed until age 4. The goal is to see if early prevention reduces malaria cases after treatment stops, compared to no prevention.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
IDRC - Tororo Research Clinic
Tororo, Uganda
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dihydroartemisinin-piperaquine (DP)
What this could lead to
If successful, this could show that preventing malaria early in life helps children build stronger immunity, reducing infections later.
What could go wrong
This is a large trial but still early-stage for this specific approach. Results may not apply to other regions, and DP may cause side effects like nausea or heart rhythm changes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.